| Serial Number | 79332232 |
| Word Mark | HUMABODY |
| Filing Date | Thursday, August 12, 2021 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, May 30, 2023 |
| Registration Number | 7064382 |
| Registration Date | Tuesday, May 30, 2023 |
| Mark Drawing | 5000 - Drawing with word(s) / letter(s) / number(s) in Stylized form |
| Published for Opposition Date | Tuesday, March 14, 2023 |
| Goods and Services | Custom manufacture of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragments, for others, for use in medical therapies, including in relation to oncology; consultancy, advice and information relating to all of the aforesaid services |
| Description of Mark | The mark consists of the wording "HUMABODY" in a stylized font. |
| Goods and Services | Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic preparations that use monoclonal antibodies, namely therapeutic pharmaceutical for treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in the discovery, preclinical and clinical development of therapeutic products for medical and veterinary purposes; pharmaceutical preparations for use in oncology; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in oncology and therapeutic treatments in relation thereto |
| Goods and Services | Chemicals used in industry and science; Chemicals for use in science and industry, namely, chemicals for laboratory research purposes; chemicals for use in science and industry, namely, chemicals for use in medical research; chemicals for use in science and industry, namely, chemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicals, namely, antibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical development, clinical development and manufacture of therapeutic products |
| Goods and Services | Licensing of intellectual property, namely, licensing of research and development; licensing of intellectual property, namely, licensing of medical therapeutic research; licensing of intellectual property, namely, licensing of research relating to antibodies and antibody fragments; licensing of intellectual property, namely, licensing of research in relation to the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments; consultancy, advice and information relating to all of the aforesaid services |
| Goods and Services | Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory research services relating to the development of antibodies and antibody fragments; oncological research; research into the development of antibodies and antibody fragments; scientific and technological services, namely, provision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicals, biologicals, antibodies and antibody fragments; engineering of antibodies and antibody fragments; scientific services, namely, discovery, preclinical and clinical development of therapeutic products; scientific research for others in the field of drug discovery, preclinical and clinical development of therapeutic and diagnostic products; research into antibodies, antibody fragments for others; research into the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments for others; consultancy, advice and information relating to all of the aforesaid services |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 4, 2022 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 4, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 4, 2022 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 3, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 045 - Legal services; security services for the protection of property and individuals; personal and social services rendered by others to meet the needs of individuals. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, February 4, 2022 |
| Primary Code | 045 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Crescendo Biologics Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Crescendo Biologics Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Crescendo Biologics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Friday, October 27, 2023 | LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
| Monday, September 25, 2023 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Thursday, August 31, 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
| Thursday, August 31, 2023 | FINAL DISPOSITION PROCESSED |
| Wednesday, August 30, 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Saturday, August 19, 2023 | RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED |
| Tuesday, May 30, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, May 30, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, March 15, 2023 | NOTIFICATION PROCESSED BY IB |
| Tuesday, March 14, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 14, 2023 | PUBLISHED FOR OPPOSITION |
| Wednesday, February 22, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, February 22, 2023 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, February 22, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, February 6, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, February 3, 2023 | EXAMINER'S AMENDMENT ENTERED |
| Friday, February 3, 2023 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, February 3, 2023 | EXAMINERS AMENDMENT E-MAILED |
| Friday, February 3, 2023 | EXAMINERS AMENDMENT -WRITTEN |
| Friday, December 16, 2022 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Friday, December 16, 2022 | FINAL REFUSAL E-MAILED |
| Friday, December 16, 2022 | FINAL REFUSAL WRITTEN |
| Tuesday, November 15, 2022 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Tuesday, November 15, 2022 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Friday, October 28, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, October 28, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, October 28, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, October 14, 2022 | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED |
| Wednesday, July 13, 2022 | REFUSAL PROCESSED BY IB |
| Sunday, July 10, 2022 | CORRECTION TRANSACTION RECEIVED FROM IB |
| Thursday, June 16, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Thursday, June 16, 2022 | REFUSAL PROCESSED BY MPU |
| Tuesday, May 24, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Monday, May 23, 2022 | NON-FINAL ACTION WRITTEN |
| Friday, May 13, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, February 8, 2022 | APPLICATION FILING RECEIPT MAILED |
| Friday, February 4, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, February 3, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |